Active Ingredient History

NOW
  • Now
Bococizumab is a drug that was in development by Pfizer targeting PCSK9 to reduce LDL cholesterol. Pfizer withdrew the drug from development in November 2016, determining that it was "not likely to provide value to patients, physicians or shareholders."   Wikipedia

More Chemistry
bococizumab | pf-04950615 | rn316 | rn-316 | rn316 antibody

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue